Kidney Health: Structure, Electrolytes, and Function

Kidney involvement is the most common feature of HNF1B-related disease, affecting nearly all patients to some degree over their lifetime ^[1]. However, the way it shows up can be very different from person to person. Doctors generally look at kidney health in two ways: the physical structure of the kidneys and their internal function (how well they filter blood and balance electrolytes).

Structural Changes

Structural issues are often the first sign of the condition, sometimes spotted on a prenatal ultrasound. These physical changes happen because the HNF1B gene is responsible for organizing the internal structures of the kidney during development ^[2].

Common structural findings include:

• Renal Cysts: Small, fluid-filled sacs within the kidney. Unlike other cystic diseases, these cysts usually do not grow large enough to cause pain ^[1].
• Hyperechogenicity: Kidneys that look “bright” or “white” on an ultrasound. This is a nonspecific finding that means the kidney tissue (parenchyma) is altered. It does not by itself prove that the kidneys are scarred or lack function, and it must be interpreted alongside kidney size, cysts, and lab results ^[3].
• Small Kidneys (Hypoplasia): One or both kidneys may be smaller than average ^[4].
• CAKUT (Congenital Anomalies of the Kidney and Urinary Tract): A broad term for structural differences, such as a kidney being in the wrong place or the tubes being shaped differently ^[1].

In rare and severe cases, a fetus may develop bilateral multicystic dysplastic kidneys, which can be life-threatening ^[5]. However, most children born with HNF1B changes have manageable kidney function that lasts for many years ^[6][7].

“Invisible” Electrolyte Issues

Even if the kidneys look relatively normal on an ultrasound, the internal tubules may not work perfectly. These tubules are responsible for reabsorbing essential minerals. When they don’t, these minerals are “wasted” into the urine.

• Hypomagnesemia (Low Magnesium): A hallmark of HNF1B disease. One pooled analysis found it in roughly 54% of patients ^[8]. Low magnesium can cause muscle cramps or fatigue. Observational cohorts suggest people with the 17q12 deletion are more likely to have low magnesium than those with an intragenic mutation ^[9].
• Hypokalemia (Low Potassium): Some patients lose too much potassium, which can lead to muscle weakness ^[8][10].
• Hyperuricemia: The kidneys may struggle to remove uric acid. If it builds up, it can sometimes cause gout—painful joint inflammation ^[11].

Measuring Function: eGFR, Blood Pressure, and Protein

To track how well the kidneys filter waste, doctors estimate the Glomerular Filtration Rate (eGFR).

• eGFR is reported in units (mL/min/1.73 m²), not as a percentage of “full health.” An eGFR of 100 does not literally mean 100% capacity; it is an estimate influenced by age, body size, and muscle mass. This is particularly difficult to compare longitudinally in growing children.
• Chronic Kidney Disease (CKD) is divided into stages based on eGFR and kidney damage. Stages 1 and 2 require evidence of kidney damage (like protein in the urine or structural cysts) even when the eGFR number is above 60. Stage 5 means the kidneys have very low function, but this does not automatically mean dialysis or transplant is required immediately ^[12].
• Urine Albumin/Protein and Blood Pressure: These are just as important as eGFR. High blood pressure or protein in the urine can damage the kidneys further and often guide treatment decisions.

Will the Disease Progress?

One of the biggest questions patients have is whether their kidney function will decline. The answer is highly variable.

• Cohort Observations: In one pediatric study, the average kidney function decline was slow (about 1 mL/min/1.73 m² per year), though individual outcomes varied greatly ^[13].
• The Genotype Difference: A large retrospective cohort study found that people with the 17q12 deletion had a slower progression to advanced CKD compared to those with intragenic mutations (the deletion group had a 70% lower hazard ratio for reaching Stage 3 CKD) ^[9].

It is vital to understand that these statistics are group averages and observational findings—they cannot predict your personal future. Ultrasound appearances and specific genetic variants are imperfect predictors. Regular tracking of your own eGFR trends, urine protein, and blood pressure is the only way to manage your individual risk ^[9].